Biogen Seeking A Path Forward After Phase III Tofersen Study Fails In ALS
Ionis-Partnered Asset Developed For SOD1 Genetic Mutations
Biogen will seek guidance from regulators and others that may illuminate a path forward for tofersen in ALS • Source: Alamy 
